^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    letrozole

    i
    Other names: CGP 20267, CGS 20267, CGS20267
    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    2d
    Emulation of the PALOMA-2 Trial (clinicaltrials.gov)
    P=N/A, N=6097, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole
    3d
    Clinical Study of Jinfeng Pill and Letrozole Combination Therapy for PCOS-Related Infertility (ChiCTR2600117547)
    P=N/A, N=264, Not yet recruiting, Shanghai First Maternity and Infant Hospital; Shanghai First Maternity and Infant Hospital
    New trial
    |
    letrozole
    3d
    Randomized Controlled Trial Comparing Letrozole-Induced Ovulation Versus Natural Cycle Single-Blastocyst Frozen Embryo Transfer on Pregnancy Outcomes in Normally Ovulatory Women (ChiCTR2500114189)
    P=N/A, N=352, Recruiting, Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
    New trial
    |
    letrozole
    3d
    The Effect of Estrogen Supplementation on Clinical Pregnancy Rate in Letrozole-Induced Ovulation: A Prospective Randomized Controlled Trial (ChiCTR2500115444)
    P4, N=420, Not yet recruiting, Dongguan People's Hospital; Dongguan People's Hospital
    New P4 trial
    |
    letrozole
    3d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    4d
    Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone. (PubMed, Anticancer Res)
    Mifepristone provided marked palliative benefit in this patient with nPR-negative, metastatic breast cancer, suggesting potential therapeutic value in similar cases. Confirmation of efficacy will require larger studies focused on tumors with absent or minimal nuclear progesterone receptor expression.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • Mifeprex (mifepristone)
    5d
    EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (clinicaltrials.gov)
    P3, N=8000, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant)
    6d
    APPOSE: Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis (clinicaltrials.gov)
    P2, N=60, Completed, University of California, San Francisco | Active, not recruiting --> Completed
    Trial completion
    |
    letrozole
    6d
    Late Cervical Recurrence of Invasive Lobular Carcinoma Ten Years After Primary Breast Cancer: A Case Report and Review of the Literature. (PubMed, Healthcare (Basel))
    The patient began systemic therapy with ribociclib plus letrozole, achieving radiologic improvement of the cervical lesion and abdominal disease. This case highlights the ability of ILC to recur after long latency and to metastasize to unusual gynecologic sites such as the cervix. We also review the literature on cervical recurrence from lobular carcinoma to emphasize the importance of gynecologic surveillance in breast cancer survivors and to identify areas that require further investigation.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
    |
    ER positive • HER-2 negative • BRCA mutation • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole
    7d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    7d
    A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov)
    P1, N=198, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide
    8d
    NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov)
    P4, N=68, Recruiting, University of Washington | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    letrozole